http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2693374-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_298e2981219b53e17f9f630bd64e3854 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-501 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4174 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4174 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate | 2014-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78aea1083d7cd22c8583b1f778aacef5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_603c79de1bc13fb961773a5173d187ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf218024e9255259a2441d1754fe9538 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4dd94624c63efad8f7c85f57c58721e1 |
| publicationDate | 2018-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2693374-T3 |
| titleOfInvention | Pharmaceutical formulations of opioid receptor modulator |
| abstract | A solid pharmaceutical dosage formulation which is a deterrent abuse formulation comprising approximately 5-20% by weight of 5 - ({[2-amino-3- (4-carbamoyl-2,6-dimethyl-phenyl) - propionyl] - [1- (4- phenyl-1H-imidazol-2-yl) -ethyl] -amino} -methyl) -2-methoxy-benzoic acid, about 60-80% by weight of lost microcrystalline cellulose, of about 0.45-1.0% by weight of colloidal silica, about 2-8% by weight of crospovidone, about 1-20% by weight of mannitol, and about 0.45-1% by weight of stearate magnesium, wherein said formulation optionally further comprises i) a film coating, or / and ii) at least one inert pharmaceutical excipient selected from a pharmaceutically acceptable dissolution rate modifying agent, a pharmaceutically acceptable plasticizer, a pharmaceutically acceptable coloring agent , a pharmaceutically acceptable opacifier, a pharmaceutically antioxidant Acceptable tea, a pharmaceutically acceptable preservative, a flavoring agent, a neutralizing agent, a buffering agent and combinations thereof. |
| priorityDate | 2013-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.